无静脉对比剂肝脏MRI检测肝细胞癌的诊断效能:病例对照可行性研究
该病例对照研究纳入175例初诊肝细胞癌患者(237个病灶)和72例无肝细胞癌的慢性肝病患者,评估无对比剂3T肝脏MRI的诊断效能。两位阅片者基于T2半傅里叶采集单次激发快速自旋回波、脂肪抑制T2快速自旋回波、T1梯度同反相位及扩散加权成像/表观扩散系数图独立判读。患者水平敏感度分别为86.3%和82.9%,特异度分别为87.5%和76.4%;病灶水平敏感度分别为75.9%和70.5%。作者认为无对比剂MRI对肝细胞癌初诊的敏感度和特异度在合理范围内,可能具有监测潜力,但需进一步验证性诊断试验。
要点
- 无对比剂MRI患者水平敏感度86.3%/82.9%,特异度87.5%/76.4%(两位阅片者)。
- 排除<1 cm病灶后敏感度升至88.0%/86.2%,小病灶是漏诊主因。
- 病灶水平敏感度75.9%/70.5%,显著低于患者水平。
核心结论
- 无对比剂MRI对肝细胞癌初诊的患者水平敏感度和特异度在合理范围内,可能具有监测潜力,但需进一步验证性诊断试验。
研究设计与样本
- 病例对照可行性研究,病例组175例初诊肝细胞癌患者共237个病灶,对照组72例无肝细胞癌的慢性肝病患者。
- 采用3T肝脏MRI,序列包括T2半傅里叶采集单次激发快速自旋回波、脂肪抑制T2快速自旋回波、T1梯度同反相位及扩散加权成像/表观扩散系数图。
- 两位放射科医师独立阅片,进行患者水平敏感度和特异度分析,并按肿瘤大小计算病灶水平敏感度。
诊断标准与关键数值
- 患者水平:阅片者1敏感度86.3%(151/175)、特异度87.5%(63/72);阅片者2敏感度82.9%(145/175)、特异度76.4%(55/72)。
- 排除<1 cm病灶后患者水平敏感度:阅片者1为88.0%(147/167),阅片者2为86.2%(144/167)。
- 病灶水平敏感度:阅片者1为75.9%(180/237),阅片者2为70.5%(167/237)。
- 病灶大小分布:<1 cm共19个,1 cm≤且<2 cm共105个,≥2 cm共113个。
临床应用与阅片要点
- 无对比剂MRI可作为肝细胞癌初诊的备选手段,但病灶水平敏感度(75.9%/70.5%)低于患者水平,阅片时需警惕小病灶漏诊。
- 排除<1 cm病灶后敏感度提升至88.0%/86.2%,提示对亚厘米病灶的检出仍是难点。
- 作者认为无对比剂MRI可能具有肝细胞癌监测潜力,但需进一步验证性诊断试验确认。
局限性
- 原文结论明确指出需进一步验证性诊断试验(further confirmatory diagnostic test accuracy studies are needed)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVE: To preliminarily evaluate the diagnostic performance of an unenhanced MRI for detecting hepatocellular carcinoma (HCC) with a case-control study design.
MATERIALS AND METHODS: The case group consisted of 175 patients with initially-diagnosed HCC, who underwent a 3T liver MRI. A total of 237 HCCs were identified. The number of HCCs that were smaller than 1 cm, 1 cm ≤ and < 2 cm, and ≥ 2 cm were 19, 105, and 113, respectively. For the control group, 72 patients with chronic liver disease, who did not have HCC, were enrolled. Two radiologists independently reviewed the T2 half-Fourier acquisition single-shot turbo spin echo, T2 fast spin echos with fat saturation, T1 gradient in- and out-of-phase images, and diffusion-weighted images/apparent diffusion coefficient maps to detect HCC. Per-patient analyses were performed to evaluate the sensitivity and specificity of the non-contrast MRI for diagnosing HCC. Furthermore, the per-lesion sensitivity was also calculated according to tumor size.
RESULTS: In the per-patient analyses, the sensitivity and specificity of reader 1 were 86.3% (151/175) and 87.5% (63/72), respectively; while those of reader 2 were 82.9% (145/175) and 76.4% (55/72), respectively. When excluding HCCs smaller than 1 cm, the sensitivity of reader 1 and 2 were 88.0% (147/167) and 86.2% (144/167), respectively. In the per-lesion analyses, the sensitivities of reader 1 and reader 2 were 75.9% (180/237) and 70.5% (167/237), respectively.
CONCLUSION: The per-patient sensitivity and specificity of non-contrast MRIs were within a reasonable range for the initial diagnosis of HCC. Non-contrast MRIs may have a potential for surveillance of HCC. Further confirmatory diagnostic test accuracy studies are needed.
引用
- Han S, Choi JI, Park MY, et al. The Diagnostic Performance of Liver MRI without Intravenous Contrast for Detecting Hepatocellular Carcinoma: A Case-Controlled Feasibility Study. Korean J Radiol. 2018. PMID: 29962863. doi:10.3348/kjr.2018.19.4.568
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。